Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of Macromolecules via Dry Powder Formulations.” The posters include data from in vitro and preclinical studies of formulations created using the company’s iSPERSE (inhaled small particles easily respirable and emittable) technology.
Pulmatrix Chief Scientific Officer and VP of Research and Development Robert Clarke said, “These data show the significant potential of iSPERSE for pulmonary delivery across a diverse range of therapies, at higher drug loads with flow rate independence and
enhanced delivery efficiency. This combination of traits differentiates iSPERSE from existing approaches by enabling the possibility of therapeutic dose delivery in lower total inhaled powder masses.”
According to the company, iSPERSE formulations of levofloxacin “showed flow rate independent performance in terms of dose and particle size distribution which could enable iSPERSE applicability across a broad range of patient populations, expanding applications beyond patients with normal lung function to also include those having lower or impaired lung function, including pediatric, elderly and those with compromised lung function.”
In addition, iSPERSE formulations of immunoglobulin G produced dense, stable powders, which could not be produced through standard spray drying techniques. The iSPERSE IgG formulation also demonstrated consistent dose delivery across flow rates from 15-60 LPM.
Read the Pulmatrix press release.
